Read more
Supreme Cannabis Revenue Soars 382% to $10M Amid Ongoing Expansion
Ryan Allway May 21st, 2019 Uncategorized The Supreme Cannabis Co. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) reported fiscal third quarter revenue that soared 382% year-over-year and 29% sequentially to $10 million. The gains were largely due to a 63% increase in recreational cannabis sales. “Revenue growth was driven by... Read more

Medical Marijuana Market To Reach USD 148.35 Billion By 2026 | Reports And Data

The Global Medical Marijuana Market is forecast to reach USD 148.35 Billion by 2026, according to a new report by Reports and Data. Marijuana is used for treating chronic pain that affects millions of people each year across the globe, thus increasing the demand for the product as a treatment procedure for medical conditions.

Read more

Read more

Read more

Read more
Emerald Health Therapeutics Introduces Unique Premium CBD Oil SYNC 25 to British Columbia Recreational Marketplace
Ryan Allway May 17th, 2019 App, News, Top News Emerald’s ultra-pure SYNC 25 CBD oil fills significant need in BC’s recreational marketplace, offering a non-THC, smoke-free alternative VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40... Read more
Halo Labs Revenue Triples After Expansion into California & Nevada
Ryan Allway May 17th, 2019 App, Exclusive, News, Top Story Halo Labs Inc. (NEO: HALO) (OTCQX: AGEEF) revenue tripled to more than $8.7 million after launching cannabis oil and concentrate operations in California and Nevada. The company’s California operations generated $5,324,396 in revenue; it’s Nevada-based business generated $514,365 in... Read more

Read more

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Inc. (TSX:IN;OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, reported financial results for the three and nine months ended March 31, 2019.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )